^
    over1year
    A positive feedback loop of heparanase/syndecan1/nerve growth factor regulates cancer pain progression. (PubMed, Korean J Pain)
    The results showed that HPSE promoted melanoma development and cancer pain by interacting with NGF/SDC1. It provides new insights to better understand the role of HPSE in melanoma and also provides a new direction for cancer pain treatment.
    Journal
    |
    SDC1 (Syndecan 1)
    |
    roneparstat (LB401)
    over2years
    Upregulation of ERK-EGR1-heparanase axis by HDAC inhibitors provides targets for rational therapeutic intervention in synovial sarcoma. (PubMed, J Exp Clin Cancer Res)
    The present study provides preclinical rationale and mechanistic insights into drug combinatory strategies based on the use of ERK pathway and heparanase inhibitors to improve the efficacy of HDACi-based antitumor therapies in SS. The involvement of classes of agents already clinically available, or under clinical evaluation, indicates the transferability potential of the proposed approaches.
    Journal
    |
    SS18 (SS18 Subunit Of BAF Chromatin Remodeling Complex) • EGR1 (Early Growth Response 1)
    |
    SS18-SSX fusion
    |
    Mekinist (trametinib) • Zolinza (vorinostat) • Istodax (romidepsin) • roneparstat (LB401)
    4years
    [VIRTUAL] Heparanase in myeloma related renal dysfunction: Role in promoting nephrotoxicity and potential as a novel biomarker for early detection. (ASCO 2020)
    HPSE causes kidney cellular injury which can be detected early by the measurement of high sensitivity biomarkers and can be prevented by treatment with HPSE inhibitors, Roneparstat and OGT-2115. Further studies are ongoing to investigate the association between HPSE activity and renal dysfunction in a larger cohort of MM patients which have been accrued as a part of the UAB-Integrative Molecular And Genetic Epidemiology (IMAGE) Study of Myeloma. Research Funding: U.S. National Institutes of Health
    KIM1 (Kidney injury molecule 1)
    |
    roneparstat (LB401)